The independent source for health policy research, polling, and news.
21-40 of 705 results
It’s been a busy week at the FDA, with a political appointee overruling agency scientists to reject an application for a new flu vaccine. Meanwhile, anti-abortion Republicans on Capitol Hill complain the agency is dragging its feet on reviewing the abortion pill mifepristone. Jackie FortiĂ©r of 51ĘÓƵ Health News, Lizzy Lawrence of Stat, and Alice Miranda Ollstein of Politico join 51ĘÓƵ Health News’ Julie Rovner to discuss these stories and more.
Lawmakers appear on the brink of passing a spending bill for the Department of Health and Human Services and a bipartisan health policy bill delayed for over a year. But the outlook is bleaker for the health care outline released by President Trump last week. Sandhya Raman of CQ Roll Call, Sheryl Gay Stolberg of The New York Times, and Paige Winfield Cunningham of The Washington Post join 51ĘÓƵ Health News’ Julie Rovner to discuss those stories and more. Also this week, Rovner interviews oncologist and bioethicist Ezekiel Emanuel to discuss his new book, “Eat Your Ice Cream.”
The government is using sickle cell treatments to test a new strategy: paying only if the therapies benefit patients. With more expensive treatments on the horizon, the program — created by the Biden administration and continued under President Trump — could help Medicaid save money and treat more patients.
An estimated 4.8 million people are expected to go without health coverage because Congress did not extend enhanced subsidies for Affordable Care Act plans. But even without a health plan, people will need medical care in 2026. Many of them have been thinking through their plan B to maintain their health.
Low-income Californians who use Wegovy and similar medications for weight loss lost their coverage at the start of the new year, with officials advising diet and exercise instead. California and other states say the drugs are too costly, even as the Trump administration announces plans to lower prices.
In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side effects.
It’s been more than 10 years since the FDA first approved an HIV prevention drug. Today, people who could benefit from preexposure prophylaxis often struggle to access the lifesaving medicine or run into doctors without the education or empathy to offer affirming care. And those lapses can produce billing headaches.
Drug industry officials and analysts praised the FDA’s plans to streamline regulation of “biosimilars,” which are cheaper alternatives to biologic drugs. But patents that block such drugs from the U.S. market are getting harder to fight.
Democrats and Republicans remain stalled over funding the federal government as Republicans launch a new attack on the Affordable Care Act. Meanwhile, the Trump administration is taking advantage of the shutdown to lay off workers from programs supported mostly by Democrats. Anna Edney of Bloomberg News, Lauren Weber of The Washington Post, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine join 51ĘÓƵ Health News’ Julie Rovner to discuss those stories and more. Also this week, Rovner interviews health insurance analyst Louise Norris about Medicare open enrollment.
In Mississippi, a state with one of the highest obesity rates in the nation, Medicaid covers weight loss drugs, but few enrollees have signed up for the benefit.
On the "Today, Explained" podcast, 51ĘÓƵ Health News' Julie Rovner recaps the TrumpRx announcement and why the direct-to-consumer initiative may not save you money on prescription drugs if you have insurance through your employer or the government.
The foreshadowed federal shutdown came after Congress failed to pass required spending bills, with Democrats demanding Republicans renew the expiring Affordable Care Act subsidies in exchange for their votes. While a shutdown does not affect Medicare and Medicaid, it could eventually hinder activities from every corner of the Department of Health and Human Services. Meanwhile, as Democrats and Republicans point fingers, HHS Secretary Robert F. Kennedy Jr. pursues policies and personnel that would undermine vaccines. Lauren Weber of The Washington Post, Shefali Luthra of The 19th, and Rachel Cohrs Zhang of Bloomberg News join 51ĘÓƵ Health News’ Julie Rovner to discuss the news. Also this week, Rovner interviews 51ĘÓƵ Health News’ Cara Anthony, who wrote a recent “Bill of the Month” feature about an out-of-network eye surgery that left one kindergartner’s family with a big bill.
In a rambling news conference that shocked public health experts, President Donald Trump — without scientific evidence — blamed the over-the-counter drug acetaminophen, and too many childhood vaccines, for the increase in autism diagnoses in the U.S. That came days after a key immunization advisory panel, newly reconstituted with vaccine doubters, changed several long-standing recommendations. Former Centers for Disease Control and Prevention official Demetre Daskalakis joins 51ĘÓƵ Health News’ Julie Rovner to discuss those stories. Meanwhile, Sandhya Raman of CQ Roll Call and Anna Edney of Bloomberg News join Rovner with the rest of the news, including a threat by the Trump administration to fire rather than furlough federal workers if Congress fails to fund the government beyond the Oct. 1 start of the new fiscal year.
Conventional wisdom says GLP-1 drugs must be taken indefinitely to maintain weight loss. But a growing number of researchers, payers, and providers are challenging that consensus and exploring whether — and how — to taper patients off expensive GLP-1 drugs.
Insurers will take drug costs, frequency of use, and other factors into account as they set premium amounts for the 2026 plan year.
It’s a difficult rite of passage for young adults without job-based insurance. Here are some tips for getting started.
Young adults without jobs that provide insurance find their options are limited and expensive. The problem is about to get worse.
The Health and Human Services secretary is winding down nearly $500 million in mRNA research funding, citing false claims that the technology is ineffective against respiratory illnesses — and notching a victory for critics of the covid vaccines. And President Donald Trump is demanding drugmakers drop their prices, quickly, but it’s unclear how he could make them comply. Lauren Weber of The Washington Post, Sandhya Raman of CQ Roll Call, and Sarah Karlin-Smith of the Pink Sheet join 51ĘÓƵ Health News’ Emmarie Huetteman to discuss these stories and more.
Health insurance generally doesn’t cover treatment for injuries sustained shortly before a customer buys a policy. A Massachusetts woman found that out the hard way.
In this second part of a two-part series on dealing with the high price of prescription drugs, experts share their insider tips.
© 2026 51ĘÓƵ